JPJohannes Pfeilschifter

Johannes Pfeilschifter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johannes Pfeilschifter has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

    by Celia Gregson, Elaine Dennison, Juliet Compston, Silvano Adami, Jonathan Adachi, Frederick Anderson, Steven Boonen, Roland Chapurlat, Adolfo Diez-Perez, Susan Greenspan, et al.

    Patients with improved health understanding have greater autonomy over, and motivation towards, health-related lifestyles. We compared self-perceived fracture risk and 3-year incident fracture rates in postmenopausal women for a range of co-morbid diseases using data from the Global Longitudinal study of Osteoporosis in Women (GLOW). GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America, Australasia. 60 393 women aged ≥55 years completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk. Annual follow-up determined self-reported incident fractures. In total, 2945/43 832 (6.7%) sustained an incident fracture over 3 years. All co-morbidities were strongly associated with increased fracture rates, particularly Parkinson’s disease (PD) (hazard ratio (HR) 95% CI; 3.89 (2.78, 5.44)), multiple sclerosis (MS) 2.70 (1.90, 3.83), cerebrovascular events 2.02 (1.67, 2.46), and rheumatoid arthritis 2.15 (1.53, 3.04), all P<0.001). Most individuals perceived their own fracture risk to be similar to (46%) or lower than (36%) women of the same age. Increased self-perceived fracture risk was strongly associated with incident fracture rates. However, only 29% of women who experienced a fracture had perceived their risk as increased. Under-appreciation of fracture risk occurred for all co-morbidities, particularly for women with neurological disease, in whom women with self-perceived low fracture risk had a fracture HR of 2.39 (1.74, 3.29) compared with women without co-morbidities. Our results suggest postmenopausal women with co-morbidities known to be associated with increased fracture rates tend to under-appreciate their risk, especially in the context of neurological diseases, where fracture rates are highest. Our findings have important implications for health education particularly among women with neurological disease and support updating of relevant guidelines.

  • Characteristics associated with anti-osteoporosis medication use: Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort

    by Pamela Guggina, Julie Flahive, Frederick H. Hooven, Nelson B. Watts, Ethel S. Siris, Stuart Silverman, Christian Roux, Johannes Pfeilschifter, Susan L. Greenspan, Adolfo Díez-Pérez, et al.


  • Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women

    by J. Pfeilschifter, C. Cooper, N. B. Watts, J. Flahive, K. G. Saag, J. D. Adachi, S. Boonen, R. Chapurlat, J. E. Compston, A. Díez-Pérez, et al.

    We examined variations in proportions of hip fractures and major fractures among postmenopausal women using the Global Longitudinal Study of Osteoporosis in Women (GLOW). The proportion of major fractures that were hip fractures varied with age and region, whereas variations in the proportion of fractures that were major fractures appeared modest.


  • Osteoporose – Was ist gesichert in der Therapie?

    by P.M. Jehle, J. Pfeilschifter

    The German Dachverband Osteologie e. V. has updated the S3 guideline "prophylaxis, diagnostic and therapy of osteoporosis in adults" ( http://www.dv-osteologie.de ). Osteoporotic fractures are a frequent cause of disability and loss of quality of life in old age. Maintenance of muscle function and balance, a daily calcium intake of 1000 mg, sufficient vitamin D and a prudent use of fall- and osteoporosis-associated drugs are key components of fracture prevention. The German guideline recommends that a specific long-term osteoporosis medication (e. g. bisphosphonates, raloxifene, strontiumranelat, parathyroid hormone) should be initiated in individuals with a 30% 10-year risk for hip fractures and vertebral fractures.


  • Osteoporose – aktuelle Diagnostik und Therapie

    by Johannes Pfeilschifter

    Osteoporotic fractures are a frequent cause of disability and a loss of quality of life in old age. Maintenance of muscle function and balance, a daily calcium intake of 1,000 mg, sufficient vitamin D, and a prudent use of fall- and osteoporosis-associated drugs are key components of fracture prevention. The German guideline recommends to initiate a specific long-term osteoporosis medication in individuals with a 30% 10-year risk for hip fractures and vertebral fractures.


  • Stellenwert des Basislabors in der Diagnostik der Osteoporose

    by J. Pfeilschifter

    Ein Basislabor ist bei jedem Patienten mit einer neu entdeckten Osteoporose obligat. Die Leitlinie des DVO zur Osteoporose empfiehlt die Bestimmung der folgenden neun Laborparameter: Serumkalzium, Serumphosphat, Kreatinin, alkalische Phosphatase, Gamma- GT, TSH, Blutbild, Eiweißelektrophorese und CRP bzw. BSG. Das Basislabor dient der Erfassung wichtiger Krankheiten, die ganz oder teilweise für die Osteoporose verantwortlich sein können, der Abgrenzung gegenüber einer Osteomalazie und der Erfassung wichtiger Einschränkungen einer medikamentösen Therapie, wie z. B. einer hochgradigen Niereninsuffizienz. Routine laboratory measurements are mandatory in the assessment of a newly diagnosed osteoporotic patient. The German osteoporosis guideline recommends the measurement of the following nine parameters: serum calcium, serum phosphate, creatinine, alkaline phosphatase, γGT, TSH, blood count, serum protein electrophoresis, and C-reactive protein or ESR. These measurements allow the detection of important secondary causes of osteoporosis, the discrimination of osteoporosis from osteomalacia, and the dectection of important limitations of medical treatment, such as advanced renal failure.